Litcius/Paper detail

Step toward repurposing drug discovery for <scp>COVID</scp>‐19 therapeutics through in silico approach

Brilliant N. Marak, Jayanta Dowarah, Laldingluaia Khiangte, Ved Prakash Singh

2020Drug Development Research30 citationsDOI

Abstract

The outbreak of SARS-CoV-2 has become a threat to global health and has led to a global economic crisis. Although the researchers worldwide are putting tremendous effort toward gaining more insights into this zoonotic virus and developing vaccines and therapeutic drugs, no vaccine or drug is yet available to combat COVID-19 effectively. Drug discovery is often a laborious, time-consuming, and expensive task. In this time of crisis, employing computational methods could provide a feasible alternative approach that can potentially be used for drug discovery. Therefore, a library of several antiparasitic and anti-inflammatory drugs was virtually screened against SARS-CoV-2 proteases to identify potential inhibitors. The identified inhibitory drugs were further analyzed to confirm their activities against SARS-CoV-2. Our results could prove to be helpful in repurposing the drug discovery approach, which could substantially reduce the expenses, time, and resources required.

Topics & Concepts

RepurposingDrug repositioningDrug discoveryDrugCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)In silicoBiopharmaceuticalPharmacologyComputational biologyRisk analysis (engineering)MedicineBiologyBioinformaticsBiotechnologyInfectious disease (medical specialty)DiseaseEcologyPathologyBiochemistryGeneSARS-CoV-2 and COVID-19 ResearchComputational Drug Discovery Methodsvaccines and immunoinformatics approaches
Step toward repurposing drug discovery for <scp>COVID</scp>‐19 therapeutics through in silico approach | Litcius